-
PRVL Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
-
ETFs
- Insider
- Institutional
- Shorts
Prevail Therapeutics (PRVL)
Company Profile
Quarter (USD) | Sep 20 | Jun 20 | Mar 20 | Sep 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 19 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 81.82 mm | 81.82 mm | 81.82 mm | 81.82 mm | 81.82 mm | 81.82 mm |
Cash burn (monthly) | 9.78 mm | 10.03 mm | 6.21 mm | 6.78 mm | 6.20 mm | 6.60 mm |
Cash used (since last report) | 511.08 mm | 524.29 mm | 324.50 mm | 354.32 mm | 323.94 mm | 345.14 mm |
Cash remaining | -429.26 mm | -442.46 mm | -242.67 mm | -272.49 mm | -242.12 mm | -263.32 mm |
Runway (months of cash) | -43.9 | -44.1 | -39.1 | -40.2 | -39.1 | -39.9 |
13F holders | Current |
---|---|
Total holders | 1 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 235.73 mm |
Total shares | 18.86 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
LLY Eli Lilly and | 18.86 mm | $235.73 mm |